ArticleFrontiers in public health2025
Global burden and forecast of infectious diseases attributable to drug use: evidence from GBD 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug use is a significant risk factor for infectious diseases, yet a comprehensive global assessment of this burden-encompassing trends, inequalities, and forecasts-is lacking, hindering progress toward World Health Organization (WHO)'s 2030 elimination targets. This study provides the first such analysis, leveraging the Global Burden of Disease (GBD) 2021 study to quantify the specific burden of infectious diseases attributable to drug use. Methods: Using data from 204 countries and territories in the GBD 2021 study, we analyzed deaths and disability-adjusted life years (DALYs) from HIV/AIDS, sexually transmitted infections (STIs), and other infectious diseases (primarily acute hepatitis B and C) attributable to drug use, following the GBD risk attribution framework. Methods included trend analysis, health inequality assessment, driver decomposition, age-period-cohort modeling, and Auto-Regressive Integrated Moving Average (ARIMA) forecasting to 2036. Results: From 1990 to 2021, the global age-standardized mortality rate (ASMR) for HIV/AIDS and STIs attributable to drug use increased by 135%, peaking around 2005 before declining, while the ASMR for other infectious diseases decreased by 57%. Males aged 30-54 carried the highest burden. Health inequality analysis revealed a shift of HIV/AIDS and STIs toward high-Socio-demographic Index (SDI) countries. Epidemiological changes were the primary driver of burden trends. By 2036, the ASMR for HIV/AIDS and STIs is projected to decline by 82.9%. Conclusion: Drug use is a critical, evolving driver of infectious disease burden. Stratified interventions and coordinated supply-demand-side governance are essential to mitigate this burden and achieve global health goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.